Abstract-We reported aldosterone as a novel adipocyte-derived factor that regulates vascular function. We aimed to investigate molecular mechanisms, signaling pathways, and functional significance of adipocyte-derived aldosterone and to test whether adipocyte-derived aldosterone is increased in diabetes mellitus-associated obesity, which contributes to vascular dysfunction. Studies were performed in the 3T3-L1 adipocyte cell line and mature adipocytes isolated from human and mouse (C57BL/6J) adipose tissue. Mesenteric arteries with and without perivascular fat and mature adipocytes were obtained from obese diabetic db/db and control db/ϩ mice. Aldosterone synthase (CYP11B2; mRNA and protein) was detected in 3T3-L1 and mature adipocytes, which secrete aldosterone basally and in response to angiotensin II (Ang II). In 3T3-L1 adipocytes, Ang II stimulation increased aldosterone secretion and CYP11B2 expression. Ang II effects were blunted by an Ang II type 1 receptor antagonist (candesartan) and inhibitors of calcineurin (cyclosporine A and FK506) and nuclear factor of activated T-cells (VIVIT). FAD286 (aldosterone synthase inhibitor) blunted adipocyte differentiation. In candesartan-treated db/db mice (1 mg/kg per day, 4 weeks) increased plasma aldosterone, CYP11B2 expression, and aldosterone secretion were reduced. Acetylcholine-induced relaxation in db/db mesenteric arteries containing perivascular fat was improved by eplerenone (mineralocorticoid receptor antagonist) without effect in db/ϩ mice. Adipocytes possess aldosterone synthase and produce aldosterone in an Ang II/Ang II type 1 receptor/calcineurin/nuclear factor of activated T-cells-dependent manner. Functionally adipocyte-derived aldosterone regulates adipocyte differentiation and vascular function in an autocrine and paracrine manner, respectively. These novel findings identify adipocytes as a putative link between aldosterone and vascular dysfunction in diabetes mellitus-associated obesity. (Hypertension. 2012;59:1069-1078.) • Online Data Supplement
A dipocytes, previously considered primarily fat storage depots, are now recognized as metabolically active endocrine/paracrine/autocrine cells that synthesize, store, and secrete hormones and proteins (adipokines). 1, 2 Adipocytes are found in subcutaneous and visceral white and brown adipose tissue and in close proximity to blood vessels, where adipokines directly influence vascular function. 1, [3] [4] [5] [6] Adipokines play a diverse role in adipose tissue biology by regulating adipocyte differentiation, fat storage, lipid metabolism, insulin sensitivity, glucose homeostasis, and inflammatory process. 1, 2 Adipocytes may contribute to the pathophysiology of obesity-associated conditions, such as diabetes mellitus, and metabolic syndrome, characterized by perivascular adipose tissue inflammation and endothelial dysfunction. 7, 8 Clinical studies show a positive correlation between plasma aldosterone levels and body mass index. 9 Concurrently, weight loss leads to blood pressure lowering and reduced aldosterone levels in obese hypertensive subjects. 10 An increased prevalence of hyperaldosteronism has been associated with obesity, suggesting that aldosterone may be a mechanistic link between adiposity and cardiovascular risk factors.
Of the many factors produced by adipocytes are components of the renin-angiotensin system. 11 In addition to angiotensin II (Ang II), adipocytes secrete mineralocorticoidreleasing factors, which stimulate steroidogenesis in human adrenocortical cells. [12] [13] [14] [15] Furthermore, aldosterone production in adrenocortical cells is increased by adipocyte-secreted mineralocorticoid-releasing factors from obese spontaneously hypertensive rats compared with lean spontaneously hypertensive rats.
14 Mineralocorticoid receptors (MRs) and glucocorticoid receptors (GRs) are present in adipocytes, whereby aldosterone influences their function. [16] [17] [18] Experimental and clinical studies demonstrated positive outcomes of MR blockade in obesity/diabetes mellitus-related cardiovascular and kidney disease. [19] [20] [21] We previously reported the presence of aldosterone in conditioned culture medium (CCM) from the 3T3-L1 adipocyte cell line. 22 Here, we investigated the molecular machinery and signaling mechanisms for aldosterone synthesis in adipocytes stimulated with Ang II. We also proposed that in diabetes mellitus-associated obesity, generation of aldosterone by adipocytes is increased and that perivascular fat (PVF) contributes to vascular dysfunction in a mineralocorticoidsensitive manner.
Methods
Please see the online-only Data Supplement for the expanded Methods section. 
Results

CYP11B2 Is Detected at Gene and Protein Levels in Adipocytes
3T3-L1
Preadipocytes Adipocytes tein). CYP11B2 protein was not detected in the presence of blocking peptide ( Figure S2A , in the online-only Data Supplement), and CYP11B2 protein was further confirmed by immunoprecipitation studies ( Figure S2B ).
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Mouse and Human Mature Adipocytes and Stromal Vascular Fraction
CYP11B2 gene and protein were detected in mature adipocytes ( Figure 1C and 1D) and in the stromal vascular fraction ( Figure S2C and S2D) isolated from C57BL/6J mouse abdominal epididymal adipose tissue. Mature adipocytes isolated from human abdominal and gluteal subcutaneous adipose tissues exhibited CYP11B2 mRNA ( Figure  1E ). CYP11B2 protein levels were also present in human mature adipocytes from gluteal subcutaneous adipose tissue ( Figure S2E ). These results demonstrate that the enzymatic machinery necessary to produce aldosterone is present in 3T3-L1 cells and mature mouse and human adipocytes (subcutaneous and visceral fat).
Adipocytes Release Aldosterone
We described previously the presence of aldosterone in CCM from 3T3-L1 preadipocytes and adipocytes. 22 Here we confirmed these data because higher levels of aldosterone were observed in CCM from 3T3-L1 adipocytes versus preadipocytes (Table) . Aldosterone production was not influenced by endogenous serum steroids, because aldosterone production by 3T3-L1 adipocytes was similar in dextran charcoal medium and in normal CCM ( Figure S3A ). To further support this, we evaluated whether mature adipocytes (mouse and human) also produce aldosterone. As shown in the Table, mature adipocytes released detectable amounts of aldosterone into the culture medium. To unambiguously demonstrate that adipocytes secrete aldosterone, high-performance liquid chromatography-mass-spectrometry studies were performed. Specific aldosterone mass transition (361.2-343.3) 23 was detected in the CCM from 3T3-L1 adipocytes ( Figure 1F ) and in the mineralocorticoid-supplemented medium ( Figure 1G ) with prominent peak eluted at 0.93 seconds. No aldosterone was detectable in control nonconditioned medium ( Figure  1H ). Together these results demonstrate that mature and 3T3-L1 adipocytes possess aldosterone synthase and secrete aldosterone.
Role of CYP11B2 in Adipogenesis
To probe the functional role of CYP11B2 in adipogenesis, we assessed effects of FAD286 (aldosterone synthase inhibitor) on 3T3-L1 differentiation. Oil-Red-O staining revealed less vesicle-containing triacylglycerol in FAD286-treated 3T3-L1 cells subjected to differentiation versus untreated differentiated 3T3-L1 adipocytes (Figure 2A ). 3T3-L1 preadipocytes, which do not contain lipid droplets, were negative for Oil-Red-O staining. Protein levels of differentiation markers, peroxisome proliferator-activated receptor-␥ and adipocyte fatty acid binding protein (aP2) ( Figure 2B ), were lower in FAD286-treated 3T3-L1 cells during the differentiation process versus untreated differentiated 3T3-L1 adipocytes.
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Components of Steroid Metabolism in 3T3-L1 Cells
Preadipocytes and adipocytes exhibited similar mRNA levels of the enzyme responsible for corticosterone synthesis, Cyp11b1 ( Figure S4A ). Gene expression of Cyp11b1 and Cyp11b2 did not differ in 3T3-L1 adipocytes ( Figure S4B ). 11-␤-Hydroxysteroid dehydrogenase type 1 (HSD11b1) converts inactive 11-dehydro metabolites to active glucocorticoids. 3T3-L1 preadipocytes and adipocytes displayed comparable levels of Hsd11b1 mRNA, whereas the protein content of the enzyme was increased in differentiated cells ( Figure  S4C ,S4D). Conversely, 11-␤-hydroxysteroid dehydrogenase type 2 (HSD11b2) oxidizes active cortisol/corticosterone to the inactive metabolites, thus preventing activation of the MR by glucocorticoids. mRNA and protein levels ( Figure S4E and S4F) of HSD11b2 were similar in 3T3-L1 preadipocytes and adipocytes. In agreement, higher levels of corticosterone were detected in CCM from differentiated 3T3-L1 adipocytes compared with preadipocytes (Table) . Basal corticosterone levels were similar in dextran charcoal medium and in normal CCM ( Figure S3B ). These findings suggest that endogenous corticosterone present in the serum of the CCM does not contribute significantly to the corticosterone levels measured in the medium in which 3T3-L1 cells are cultured.
MR and GR Expression in 3T3-L1 Cells
The receptors through which aldosterone and corticosterone mediate their effects, the MR (Nr3c2 gene) and the GR (Nr3c1 gene) were evaluated. MR mRNA and protein content did not differ between preadipocytes and adipocytes ( Figure  S5A and S5B). mRNA levels of GR were slightly higher in 3T3-L1 preadipocytes compared with adipocytes, whereas similar levels of protein were detected before and after the differentiation process ( Figure S5C and S5D).
Effects of Ang II on 3T3-L1 Adipocyte-Secreted Aldosterone
Ang II increased CYP11B2 expression after 24 hours of stimulation ( Figure 3A ) but not at earlier time points (data not shown). This effect was paralleled by the increase in adipocyte-secreted aldosterone ( Figure 3B and Table) , which was abolished by FAD286 in cells cultured in normal medium and in dextran charcoal medium ( Figure 3B and S3A). Ang II-induced effects on CYP11B2 expression and on aldosterone secretion were inhibited by candesartan, an Ang II type 1 receptor (AT 1 R) antagonist, but not by the Ang II type 2 receptor antagonist, PD 123319 ( Figure 3C and 3D). Losartan, another selective AT 1 R antagonist, also decreased Ang II-induced aldosterone secretion (data not shown). Ang II increased corticosterone content in normal and dextran charcoal CCMs (Table and Figure S3B ), although a smaller effect of Ang II was observed in the charcoal CCM ( Figure  S3B ). The effect of Ang II on corticosterone production was unaffected by FAD286, suggesting that this compound selectively inhibits aldosterone synthesis ( Figure S3B ). Adipocyte protein contents of MR, GR, HSD11b1, and HSD11b2 were not affected by Ang II ( Figure S6 ).
Molecular Mechanisms Underlying Ang II-Induced Aldosterone Production by Adipocytes
Calcineurin is a modulator of the CYP11b2 gene in adrenal cells. 24 The calcineurin inhibitors cyclosporin A and tacrolimus (FK506) prevented Ang II-induced aldosterone secretion by 3T3-L1 adipocytes ( Figure 4A ). Nuclear factor of activated T cells (NFAT), a calcineurin-targeted transcription factor, once dephosphorylated translocates to the nucleus and triggers genomic events. 25 Ang II-induced aldosterone secretion by 3T3-L1 adipocytes was prevented with VIVIT, an inhibitor of calcineurin-mediated dephosphorylation of NFAT ( Figure 4B ). In 3T3-L1 adipocytes, Ang II timedependently induced nuclear translocation of NFATc4, the isoform expressed primarily in nonimmune systems ( Figure  5A ). This was prevented by candesartan ( Figure 5B ). NFATc4 activation induced by Ang II in 3T3-L1 adipocytes was confirmed by the decrease of its phosphorylation ( Figure  5C ). Ang II-induced NFATc4 dephosphorylation was calcineurin dependent, because effects were inhibited by cyclosporin A and FK506 ( Figure 5D ).
Adipocyte-Derived Aldosterone in a Mouse Model of Diabetes Mellitus-Associated Obesity
Body weight and plasma glucose levels were elevated in db/db mice, a model of obesity and diabetes mellitus compared with control db/ϩ mice (Table S2 ). Plasma aldosterone was higher in db/db mice ( Figure 6A ). Mature adipocytes isolated from abdominal epididymal adipose tissue of db/db mice secreted a greater amount of aldosterone into the CCM and displayed higher Cyp11b2 mRNA expression ( Figure 6B and 6C) compared with cells from db/ϩ mice. No differences were observed in Gr, Mr, and Hsd11b1 mRNA levels in mature adipocytes from db/ϩ and db/db mice, whereas gene expression of Hsd11b2 was greater in cells from db/db mice ( Figure S7A through S7D). Cyp11b1 mRNA expression was similar and corticosterone levels were higher in mature adipocytes from db/db as compared with db/ϩ mice ( Figure  S7E and S7F). Expression of CYP11B2 (mRNA and protein; Figure S8A and S8B) did not differ in stromal vascular cells from db/db and db/ϩ mice.
CYP11B2 Expression and Aldosterone Release From Mature Adipocytes Isolated From Candesartan-Treated db/db Mice
Candesartan treatment normalized the increased plasma aldosterone levels, aldosterone secretion into the CCM by mature adipocytes, and adipocyte Cyp11b2 gene expression observed in db/db mice ( Figure 6 ). Candesartan had no effect on mature adipocytes from db/ϩ mice ( Figure 6 ). Candesartan did not affect body weight, plasma glucose levels, and systolic blood pressure in both animal groups (Table S2) .
Effect of Adipocyte-Derived Aldosterone on Vascular Function in db/db Mice
Endothelium-dependent and endothelium-independent relaxation induced by acetylcholine (ACh) and by diethylamine NONOate (DEA-NO) in norepinephrine-precontracted arteries were impaired in mesenteric arteries from db/db mice ( Figure 7A and 7B and Table S3 ). The presence of PVF did not affect relaxation responses to ACh and DEA-NO in arteries from db/ϩ and db/db mice ( Figure 7A and 7B and Table S3 ). In arteries from db/ϩ mice, the MR antagonist eplerenone had no effect on endothelium-dependent ( Figure  7C ) and independent ( Figure 7D ) responses in the absence or presence of PVF. In arteries from db/db mice, eplerenone improved ACh-induced relaxation in the presence of PVF, whereas no effect of the antagonist was observed in the absence of PVF ( Figure 7E ). Eplerenone did not affect DEA-NO relaxant response either in the presence or absence of PVF in arteries from db/db mice ( Figure 7F ). Observed effects are independent of vascular mechanical changes, because the stress-strain curve was similar in arteries with and without PVF ( Figure S9 ). 
Expression of MR and GR in Mesenteric Arteries From db/db and db/؉ Mice
Mesenteric arteries from db/db mice displayed higher protein levels of MR but not GR versus db/ϩ mice ( Figure S10A and S10B).
Discussion
Major findings of the present study are that adipocytes possess functionally active aldosterone synthase and are aldosterone-producing cells. In support of this novel paradigm are the following: (1) adipocytes possess mRNA and protein CYP11B2; (2) Ang II/AT 1 R regulates CYP11B2 expression and adipocyte-secreted aldosterone in a calcineurin/NFAT-dependent manner, an effect blocked by FAD286 (selective CYP11B2 inhibitor); (3) expression of CYP11B2 and production of aldosterone are increased in mature adipocytes isolated from db/db mice, a model of diabetes mellitus-associated obesity; and (4) endothelial dysfunction in arteries from db/db mice is improved by eplerenone in the presence of PVF. These findings uncover adipocyte-derived aldosterone as a potential pathogenic factor in obesity-associated vascular disease.
Obesity/adiposity is associated with increased plasma levels of aldosterone. Compelling evidence suggests that adipocyte secretory products directly stimulate adrenocortical aldosterone secretion. [12] [13] [14] [15] Our previous study indicated that adipocytes are a secondary source of aldosterone. 22 Such potentially steroidogenic activity was confirmed with the observation that preadipocytes and, to a greater extent, adipocytes contain CYP11B2. Of importance, this locally produced aldosterone might have an autocrine (patho)physiological role by influencing, among other processes, adipocyte differentiation. 16, 17, 19, 26 Our findings demonstrate that the selective CYP11B2 inhibitor FAD286 prevented adipocyte differentiation, triacylglycerol accumulation, and expression of adipocyte differentiation markers peroxisome proliferator-activated receptor-␥ and aP2. In support of these data, MR-gene knockout adipocytes fail to accumulate lipids. 26 Adipocytes also possess CYP11B1 and secrete corticosterone. In our study, we cannot rule out the possibility that adipocyte-derived corticosterone, through MR, influences adipocyte differentiation and function. Previous studies showed that aldosterone promotes 3T3-L1 preadipocyte differentiation through MR but not through GR. 16 Ang II is an endogenous stimulus for adrenal aldosterone secretion. Adipocytes exhibit all of the components of the renin-angiotensin system, including AT 1 R and Ang II type 2 receptor receptors, whereby Ang II mediates local effects, including adipocyte growth, differentiation, inflammation, oxidative stress, and lipolysis. 11 We found that, in 3T3-L1 adipocytes, Ang II stimulated an increase in CYP11B2 expression and secretion of aldosterone, effects blocked by AT 1 R antagonists. Ang II-induced aldosterone secretion was also abolished by FAD286, suggesting AT 1 R-mediated activation of adipocyte CYP11B2. Ang II did not affect the protein content of MR, GR, HSD11b1, or HSD11b2 in 3T3-L1 adipocytes, indicating that Ang II-mediated adipocyte effects are not generalized phenomena but highly regulated and specific.
In adrenal cells, CYP11B2 transcription involves calcineurin. 24 A major pathway regulated by calcineurin involves activation of NFAT. Calcium-mediated signaling activates calcineurin phosphatase, which dephosphorylates NFAT and induces its nuclear translocation after the regulation of genomic events. 27 Four genes encoding NFAT proteins (NFATc1, NFATc2, NFATc3, and NFATc4) have been identified. NFATc4 has been implicated in multiple biological processes, including adipocyte differentiation through transactivation of the aP2 promoter and by increasing peroxisome proliferator-activated receptor-␥ expression. 28 Ang II activates calcineurin-NFAT signaling in many cell types, including vascular smooth muscle cells. 29 However, to our knowledge, involvement of NFAT in aldosterone synthesis has not been reported. Here we show that molecular mechanisms underlying Ang II-induced aldosterone synthesis in adipocytes is related to the calcineurin-NFAT pathway because of the following: (1) calcineurin inhibitors and the specific NFAT inhibitor, VIVIT, abrogated Ang II-induced aldosterone secretion by adipocytes; (2) Ang II stimulated NFAT nuclear translocation, an effect blocked by candesartan; and (3) Ang II decreased NFATc4 phosphorylation, which was restored by cyclosporin A and FK506.
To investigate the pathophysiological significance of our findings in the context of obesity, we explored the possibility that the adipocyte CYP11B2-aldosterone-MR axis is upregulated in db/db mice, a model of diabetes mellitus-associated obesity. We used this model based on clinical evidence clearly demonstrating that obesity is strongly associated with diabetes mellitus in humans. Diabetic db/db mice displayed elevated plasma aldosterone levels. Moreover, mature adipocytes isolated from db/db mice showed higher CYP11B2 expression and secreted greater amounts of aldosterone than those from db/ϩ mice. CYP11B2 content did not differ in the stromal vascular fraction between experimental groups, indicating that the nonadipocyte fraction in adipose tissue may not contribute significantly to the elevated aldosterone levels in db/db mice. A limitation of the present study is that we have not directly assessed whether increased adipocytederived aldosterone translates into changes in plasma aldosterone levels or whether adrenal aldosterone might be accumulated, in part, in adipose tissue. Such studies in adrenalectomized mice and in mice in which adipocyte CYP11B2 is knocked out should elucidate this aspect. In addition, future studies in diet-induced obesity models without concomitant diabetes mellitus will elucidate whether diabetes mellitus, per se, is a confounding factor contributing to findings observed in our study.
Because the renin-angiotensin system is activated in obesity 11 and because our study revealed Ang II as a potent stimulus of adipocyte-secreted aldosterone, we questioned whether AT 1 R plays a role in the increased systemic and adipocyte-derived aldosterone levels in db/db mice. Candesartan treatment normalized the increased CYP11B2 expression and elevated adipocyte-derived aldosterone and plasma levels of the mineralocorticoid in db/db mice. These effects were independent of hemodynamic changes, because candesartan did not alter blood pressure. Our results are in agreement with studies in humans that reported greater Ang II-stimulated aldosterone production in normotensive overweight subjects than in lean subjects. 30 Vascular inflamma- tion, insulin sensitivity, adipocyte hypertrophy, and altered differentiation are prevented by AT 1 R blockade in diabetes mellitus. 31 Together these observations highlight some putative molecular mechanisms underlying beneficial effects of renin-angiotensin system/aldosterone blockade in metabolic syndrome or obesity. 8, 32 Functionally increased aldosterone bioavailability in adipose tissue may have autocrine and paracrine actions. We showed an autocrine role in adipogenesis because aldosterone synthase inhibition blocked differentiation. In support of our findings, eplerenone reduced the number of hypertrophic adipocytes in obese db/db and ob/ob mice. 20 In a paracrine fashion, adipocyte-secreted aldosterone may modulate microvascular tone. Adipose tissue secretory products include vasoactive factors that directly influence vascular tone. 4, 5 In obesity, dysregulation of adipocyte-derived vasoactive factors results in vasoconstriction predominating over vasodilation and the loss of physiological anticontractile properties of PVF. 33, 34 Small arteries from db/db mice exhibited endothelial dysfunction as described. 8 The presence of PVF did not affect relaxation to either ACh or DEA-NO in arteries from db/db or db/ϩ mice. However, in arteries surrounded by PVF from db/db mice, acute eplerenone pretreatment improved ACh-induced relaxation, suggesting that contractile substances derived from PVF, possibly aldosterone and/or glucocorticoids, activate MR contributing to the endothelial dysfunction in db/db mice. Whether chronic eplerenone treatment would normalize these effects remains an attractive hypothesis. The beneficial effect of eplerenone seems to be independent of vascular smooth muscle cell sensitivity to NO, because the MR antagonist did not affect DEA-NO-induced relaxation. Importantly, mesenteric arteries from db/db mice showed greater MR expression than db/ϩ but similar GR expression. These findings suggest that MR downstream pathways might be increased in arteries from db/db mice that may also contribute to the observed phenomena. Mechanisms whereby aldosterone/MR influences endothelial dysfunction in obesity await further clarification, but reactive oxygen species and/or cyclooxygenase byproducts may be important. 35 Eplerenone and free radical scavengers restored the loss of anticontractile properties of PVF induced by aldosterone in mice. 36 In conclusion, we provide evidence that adipocytes possess functionally active aldosterone synthase that generates aldosterone, processes regulated by Ang II through AT 1 Rmediated activation of calcineurin/NFAT signaling pathways. Adipocyte-derived aldosterone, which is increased in db/db mice, regulates adipocyte differentiation in an autocrine manner and vascular function in a paracrine fashion. MR activation, by PVAT-derived factors, is implicated in obesity-associated vascular dysfunction (Figure 8 ). Our findings identify adipocytederived aldosterone as a putative molecular mechanism underlying aldosterone-related vascular risk, particularly in the context of diabetes mellitus-associated obesity.
Perspectives
Our data demonstrate that adipocytes produce aldosterone through Ang II-mediated aldosterone synthase regulated by calcineurin. These findings add novel information to the reported adipocyte-secreted mineralocorticoid-releasing factors, which stimulate steroidogenesis in adrenocortical cells. [12] [13] [14] [15] Interestingly, the contribution of Ang II seems to be different in adipocyte-derived aldosterone production and in aldosterone-releasing activity of adipocytes on adrenal cells highlighting a complex role of Ang II in the adipocyteadrenal cell axis and its contribution to aldosterone release. Our data could have major significance in clinical medicine, Figure 8 . Scheme illustrating the putative link among adipocytes, aldosterone, the renin-angiotensin system and obesity-associated vascular dysfunction. Adipocytes secrete aldosterone, which participates in lipid formation and adipocyte differentiation. Ang II, produced locally or systemically, regulates aldosterone secretion from adipocytes through the calcineurin/nuclear factor of activated T cells (NFAT) pathway. In obesity, upregulation of adipocyte CYP11B2 promotes aldosterone production. Adipocyte-derived aldosterone might contribute to enhanced adipogenesis and adipocyte hypertrophy in an autocrine fashion. Adipocyte-produced aldosterone and/or glucocorticoids through a paracrine mechanism activate vascular mineralocorticoid receptors participating in obesity-associated endothelial dysfunction. Ang II indicates angiotensin II; CYP11B2, aldosterone synthase; MR, mineralocorticoid receptor; AT 1 R, angiotensin type I receptor; p, phosphorylation.
particularly in the understanding of why hyperaldosteronism and associated adiposity/obesity are becoming increasingly important conditions in cardiovascular medicine in current times. Our study further supports the idea that, by targeting adipocytes, MR blockade might be an important therapeutic tool in obesity and/or metabolic syndrome/diabetes mellitusassociated vascular alterations. 
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Cell culture
Cell lines were obtained from the American Type Culture Collection (Manassas, VA). Studies were performed in murine 3T3-L1 preadipocytes and 3T3-L1 adipocytes. Y1 mouse-derived and H295R human-derived adrenal cells, were used as positive controls, and cultured under manufacturer specified conditions.
Differentiation protocol for 3T3-L1 preadipocytes
3T3-L1 preadipocytes were grown in monolayer culture in DMEM supplemented with 10% calf serum and antibiotics (0.1 mg/mL streptomycin and 100 U/mL penicillin) in 5 % CO 2 , at 37º C. Two days post confluence the differentiation process was started by culturing 3T3-L1 in DMEM supplemented with 10% FBS, 0.5 mmol/L 3-isobutyl-1-methylxanthine, 0.25 mol/L dexamethasone, and 1 µmol/L insulin for 2 days. 1 Medium was replaced by DMEM supplemented with 10% FBS, and 1 mol/L insulin for an additional 2 days. Subsequently, the medium was replaced by DMEM containing only 10% FBS for 4 days. At the end of the differentiation period the cells exhibited adipocyte morphology and were maintained in DMEM supplemented with 1% calf serum and antibiotics overnight before stimulation.
In a parallel set of experiments, to evaluate the possible influence of endogenous steroids in the different serums, 3T3-L1 preadipocytes were differentiated and stimulated as described above using dextran charcoal FBS and CBS (Sigma-Aldrich).
Isolation and culture of mature adipocytes and stromal vascular cells (SVC) from mouse adipose tissue
Mouse mature adipocytes
Mice were purchased from Jackson Laboratories (Maine, USA 
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containing 1% BSA for 20-30 min in a rotating shaker at 37ºC. After digestion, the same volume of DMEM/F12 was added to the sample mixture which was filtered through a 200 m mesh and centrifuged at 50x g for 5 min. The pellet was discarded. The infranatant was kept for stromal vascular cells (SVC) isolation. The floating mature adipocytes fraction was transferred into a new tube containing DMEM/F12 and centrifuged (50x g, 5 min). The floating mature adipocytes fraction was washed in DMEM/F12 twice. After the last centrifugation, the mature adipocytes were placed in 500 µL of -MEM containing 15 mmol/L HEPES, 17 nM insulin and 1% FBS and incubated in 5 % CO 2 , at 37°C for 24 hr.
Human abdominal and gluteal subcutaneous mature adipocytes
Adipose tissue was obtained from subjects undergoing elective abdominal surgery. Adipose tissue was dissected to remove connective tissue and capillaries, then digested with collagenase type I (600 U/mg of tissue; Worthington, Lakewood, NJ). The digested tissue was filtered through a 200 m filter, centrifuged at 150 x g for 10 min. Adipocytes were transferred to new tubes and repeatedly washed with Krebs-Ringer-Hepes buffer supplemented with 1% BSA and antibiotics (100 U/mL penicillin, 0.1 mg/mL streptomycin, and 50 mg/mL nystatin). Cells were placed in DMEM supplemented with 1% BSA, and 15 mmol/L HEPES pH 7.4, for 2 hr and processed for mRNA extraction.
Gluteal subcutaneous biopsies were obtained under local anesthetic from healthy normotensive male subjects (aged 30 to 60 years) as previously described. 2 Subcutaneous adipose tissue was carefully cleaned of arteries and connective tissue. After mincing, the tissue was digested with collagenase type I (0.5 mg/mL/g tissue) in Krebs-Ringer HEPES buffer containing 1% BSA for 20-30 min in a rotating shaker at 37ºC. Mature adipocytes were isolated as described above and maintained for 24 hr in -MEM containing 15 mmol/L HEPES, 17 nmol/L insulin and 1% FBS.
Mouse SVC
The SVC were isolated from mouse adipose tissue. After collagenase digestion, filtration and centrifugation as described above, the pellet was discarded and the supernatant containing floating adipocytes was collected. The remaining infranatant was collected and mixed with DMEM/F12. After centrifugation at 200x g for 10 min, the supernatant was adjusted for 5 mL, without disturbing the pellet, and 10 mL of erythrocytes lysis buffer (in mmol/L: 155 NH 4 Cl 2 , 5.7 K 2 HPO 4 , 0.1 EDTA) was added. The mixture was gently vortexed. After 5 min incubation, the same volume of DMEM/F12 with 10% FBS was incorporated to the mixture and the pellet was carefully resuspended. The mixture was then filtered through 20 m mesh, centrifuged at 200x g for 5 min and the pellet was resuspended in DMEM/F12 with 10% FBS and antibiotics. The SVC were seeded and kept in culture at 37ºC. Cells were used between passages 0 and 2.
Protocols for cell stimulation
3T3-L1 adipocytes were stimulated with 1, 10 and 100 nmol/L Ang II for 24 hrs. Ang II 1 nM was used for short ( 
Conditioned culture medium
The conditioned culture medium (CCM) was collected from mouse and human mature adipocytes, 3T3-L1 preadipocytes and stimulated and non-stimulated 3T3-L1 adipocytes. For mature adipocytes, CCM was collected 24 hr after isolation. 3T3-L1 adipocytes CCM was collected 24 hr after differentiation process. 3T3-L1 preadipocytes were cultured in parallel for media collection. For stimulated-3T3-L1 adipocytes, the medium was collected after 24 hr in the presence of Ang II. CCM was kept at -20ºC for further aldosterone and corticosterone determinations. Cells were further processed for protein and mRNA procedures.
Oil Red O staining
3T3-L1 preadipocytes were seeded into 6-well plates and grown until they reached confluence. Two days after confluence, the cells were treated with adipogenic inducers as described in the differentiation protocol, in the absence or in the presence of the aldosterone synthase inhibitor FAD286 (1 µmol/L), throughout the differentiation process. Eight days after induction of differentiation, cells were washed twice with PBS and fixed with 10% formalin at 24 o C for 1 hr. After fixation, cells were stained in freshly and diluted Oil Red O solution (3 parts of 0.6 % Oil Red O in isopropyl alcohol and 2 parts of water) for 2 hr. After repeatedly washing with water, cells were visualized microscopically (10x objective).
Western blot analysis
3T3-L1 cells were lysed for western blotting with buffer containing: 50 mmol/L Tris, pH 7.4; 5 mmol/L EGTA, 2.5 mmol/L EDTA, 1 mmol/L Na 2 VO 3 , 1 mmol/L PMSF, 1 µg/mL pepstatin A, 1 µg/mL leupeptin, and 1 µg/mL aprotinin and 0.5 % Triton x-100. For mature adipocytes, proteins were precipitated with 10% trichloroacetic acid, and resuspended in 0.1 mol/L NaOH and 2x Laemmli buffer. Equal amounts of protein (40 g for 3T3-L1 cells, 30 g for SVC, and 50-100 g for mature adipocytes) were separated by electrophoresis on a 10% SDS-polyacrylamide gel and transferred onto a nitrocellulose membrane (Bio-Rad). Nonspecific binding sites were blocked with 5% skim milk in Tris-buffered saline solution with 0.1 % Tween-20 for 1 hour at 24°C. Membranes were then incubated with specific antibodies overnight at 4°C. Antibodies were as follows: anti-CYP11B2 (1:500, Chemicon International, Millipore, Billerica, MA, USA. #MAB6021), anti-CYP11B2 (1:500, #sc-32372) in the absence or in the presence of its corresponding blocking peptide (Santa Cruz Biotechnology, CA, USA), anti-CYP11B2 (1:500) (provided by Dr. Gómez-Sánchez, Division of Endocrinology, Montgomery VA Medical Center, Jackson, USA), anti-mineralocorticoid receptor (MR, 1:500 Santa Cruz Biotechnology, #sc-11412), anti-glucocorticoid receptor (GR, 1:1000, Santa Cruz Biotechnology, #sc-1004), anti-11β-hydroxysteroid dehydrogenase type 1 (HSD11b1, 1:500 Santa Cruz Biotechnology, #sc-20175), anti-11β-hydroxysteroid dehydrogenase type 2 (HSD11b2, 1:500 Santa Cruz Biotechnology, #sc-20176), antiperoxisome proliferator-activated receptor gamma (PPAR, 1:1000, Santa Cruz Biotechnology, #sc-7273), anti-adipocyte P2 (aP2, 1:1000, R&D Systems, #AF1443), anti-phospho NFATc4 (Ser 168, 170 , 1:500, Santa Cruz Biotechnology, #sc-32630), antiNFATc4 (1:500, Santa Cruz Biotechnology, #sc-271091). Membranes were incubated with horseradish peroxidase-conjugated secondary antibodies for 1hr at room temperature. Thereafter signals were detected by chemiluminescence and visualised by autoradiography. The same membrane was used to determine -actin expression as an internal housekeeping control using a mouse monoclonal antibody (1:10,000, Sigma Chemical Co). Blots were analyzed densitometrically using the Scion Image software.
Nuclear translocation of NFAT
3T3-L1 adipocytes were stimulated with Ang II, washed, and suspended in hypotonic buffer. The swollen cells were homogenized and nuclei were pelleted (8000x g for 15 min, 4°C). Supernatant containing the cytoplasmic fraction was collected. Nuclei were resuspended in a high-salt buffer (30 mins, 4°C) and centrifuged (13000x g for 30 min). The supernatant was collected as nuclear extract. Cytosolic and nuclear fractions were used for western blotting (30 µg of protein). Membranes were incubated with monoclonal mouse antibody anti-NFATc4 (1:500 Santa Cruz) and the anti-TATA box Binding Protein (TBP) antibody (1:1000, Abcam, Cambridge, MA, USA), as a marker for the nuclear fraction.
Immunoprecipitation
For immunoprecipitation experiments, 3T3-L1 preadipocyte and adipocyte homogenates were adjusted to equal protein concentration (500 µg) and volume (500 µL). Mouse adrenal gland (300 µg protein) was used as a positive control. Protein samples were then incubated with 2 µg of mouse CYP11B2 monoclonal antibody (Chemicon International) overnight at 4 o C. CYP11B2 immune complexes were immunoprecipitated with protein agarose beads for 2 additional hours. Precipitated immune complexes were washed 2 times in cold PBS. Proteins were eluted from the beads with SDS sample loading buffer. Immunoprecipitates were resolved in 10% SDS-polyacrylamide gels and transferred to nitrocellulose membrane. Immunoblotting of CYP11B2 immunoprecipitates was undertaken with mouse anti-CYP11B2 antibody (1:500). Secondary antibody signals were revealed by chemiluminescence, visualized by autoradiography. Isotype-matched IgG control immunoprecipitations lacking primary antibody were performed on lysates to indicate background binding. In order to decrease the interference of the heavy IgG chain in the immunoblot assays, ExactaCruz system (beads and secondary antibody) was used (Cruz Biotechnology).
Aldosterone and corticosterone measurements
Aldosterone and corticosterone concentrations were determined in CCM from 3T3-L1 preadipocytes and adipocytes, mouse and human mature adipocytes and mouse plasma by enzyme immunoassay (EIA) (Cayman Chemical, Ann Arbor, MI, USA) according to the manufacturer´s instructions. CCM from adipocytes was concentrated in speed vacuum system (Vacufuge Eppendorf). Standard curves were derived using non-conditioned medium and blank measurement of non conditioned medium was substracted from all samples. Blood samples were collected into heparinized tubes, centrifuged at 2000 g at 4ºC and plasma was further stored at -80ºC until analysis. Table S1 . PCR was performed in duplicate for each sample using a PCR Master mix for SYBR Green I (Applied Biosystems) containing 300 nmol/L primers, and 3 µL template cDNA in 25 µL total volume. PCR conditions consisted of an activation step of the Hot Gold Start Taq DNA polymerase (95°C) for 10 min, followed by 40 cycles of 10 secs at 95°C (denaturation step) and 1 min at 60°C (primer annealing, extension, and fluorescence acquisition). Serial dilution of pooled cDNA was used in each experiment to assess PCR efficiency. Ubiquitin C (UBC) or hypoxanthine guanine-phosphoribosyl-transferase (HPRT) housekeeping genes were used as the reference gene for normalization. The relative copies number of the target genes were calculated with the 2 (-Ct) method, after assessment that PCR efficiency was 100%.
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HPLC and Mass Spectrometry Analysis
The presence of aldosterone in the adipocyte CCM was further confirmed by high performance liquid chromatography (HPLC)-mass spectrometry (MS). 5 mL of CCM was collected from 3T3-L1 cells and proteins were precipitated using cold methanol (4°C, 3:1, methanol:sample followed by centrifugation at 10000 g for 10 min). Samples were then dried using a speedvac concentrator (Thermo Scientific) and resuspended in 5 ml of the initial chromatographic solution (20% methanol). Aldosterone was separated by HPLC using a Waters C18 analytical column (50 x 3.9 mm, 4 µm) at 24 o C and monitored by ultraviolet detection (254 nm). The limit of detection for this system was 10 ng/mL approximately. HPLC separation was achieved with a gradient of solutions A (20% Methanol) and B (100% Methanol) at a flow rate of 0.5 mL/min. Runs were started with 0% solution B (100% solution A) increasing linearly to 50% solution B during the initial then to 100% solution A for the final 10 min. Total run time was 25 min. Under such chromatographic conditions, the retention time for aldosterone was approximatly 10.3 min ( Figure S1 ). Fractions were collected at 10-10.5 mins, a time corresponding to the observed retention time of exogenously added aldosterone. The presence of aldosterone in fractionated samples was then confirmed by HPLC-triple stage quadrupole MS (TSQ Quantum Access Max, Thermo Electron). Chromatography was performed on a Hypersil Gold column (50 x 2.1 mm, 1.9 µm, Thermo Scientific) with a gradient of solutions A: 0.1% formic acid in water and B: 100% Methanol. The initial chromatographic conditions were 65% solution B which was increased to 90% solution B over 2 min. These conditions were then held for one min, after which the conditions returned to 65% B over the remaining 2 min. Total run time was 5 min. Under positive electrospray conditions (3000 V) aldosterone was identified by selective reaction monitoring (aldosterone 361.200-343.3 m/z). Data collection and analyses were conducted with the use of Xcalibur software (Thermo Scientific).
In vivo studies
Db/db and db/+ mice were treated with candesartan (1 mg/kg/day) for 4 weeks. Candesartan or vehicle were administered daily by subcutaneous injection. Systolic blood pressure (SBP) was measured weekly by tail-cuff methodology. Mice were killed by decapitation under anesthesia. At the end of the treatment, plasma and abdominal epididymal adipose tissue were obtained. Mature adipocytes and SVC were isolated and cultured as described above.
Vascular studies
Second order branches of mesenteric artery with and without perivascular fat (PVF) were isolated from 18 week-old db/db and db/+ mice and mounted on a pressurized myograph (Living Systems, Burlington, Vermont). Vessel segments (2 to 3 mm long) were slipped onto 2 glass microcannulas, one of which was positioned until vessel walls were parallel, and equilibrated in physiological salt solution (in mmol/L: 120 NaCl, 25 NaHCO 3 , 4.7 KCl, 1.18 KH 2 PO 4 , 1.18 MgSO 4 , 2.5 CaCl 2 , 0.026 EDTA, and 5.5 glucose), continuously bubbled with 95% O 2 and 5% CO 2 to achieve a pH of 7.4 at 37°C and pressurized to 45 mmHg. Endothelium-dependent and -independent relaxations in the absence and in the presence of the mineralocorticoid receptor antagonist eplerenone (10 µmol/L) were assessed by measuring dilatory responses to acetylcholine (ACh, 1 nmol/L to 10 µmol/L) and diethylamine NONOate (DEA-NO, 1 nmol/L to 50 µmol/L), respectively, in vessels pre-contracted with norepinephrine (NE) at a concentration to achieve approximately 70% of maximal response. Thereafter, vessels were deactivated with 0Ca 2+ -physiological salt solution containing 10 mmol/L EGTA to eliminate myogenic tone before measuring vascular structure and mechanics. Vascular functional responses and structural and mechanical parameters were calculated as previously described.
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Angiotensin II was obtained from Bachem (Torrance, CA, USA). IBMX, insulin, dexamethasone, PD123319 salt hydrate, and cyclosporin A were obtained from Sigma Chemical, Co. Eplerenone was obtained from Santa Cruz. Candesartan was provided by AstraZeneca (Mississauga, ON, Canada). FK506 was obtained from AG Scientific (Vancouver, BC, Canada) and VIVIT from Calbiochem. FAD286 was provided to Dr C. Gómez-Sánchez by Novartis. FAD286, candesartan, FK506, and cyclosporin A were dissolved in dimethylsulfoxyde (DMSO), and dexamethasone was dissolved in 100% ethanol. Eplerenone was dissolved in 100% ethanol. Ang II and insulin were dissolved in distilled water.
Data Analysis
Results are presented as mean±SEM. Comparisons were performed by Student t test, oneway ANOVA followed by Newman-Keuls test, and 2-way ANOVA, as appropriate. A value of P<0.05 was considered statistically significant. 
